lobbying_activities: 2380069

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2380069	119f2d06-0e97-45e1-b55f-bef2d8600aa0	Q4	ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC)	1466	ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC)	2019	fourth_quarter	MMM	On December 2, 2019, AACC joined with other members of the healthcare community in writing to the House and Senate in support of H.R.3584, the Laboratory Access for Beneficiaries (LAB) Act, which would delay the reporting of lab financial data for one year and require the Medicare Payment Advisory Committee (MedPAC) to conduced a study on the payment methodology used by the Centers for Medicare Services for reimbursing clinical laboratories. On December 5, 2019, AACC met with House and Senate lawmakers and staff in support of H.R.3584, the LAB Act. On December 11 & 18, 2019, AACC conducted a grassroots campaign targeted towards House and Senate members in support of H.R.3584. On October 3, 2019, AACC conducted a congressional briefing on point of care testing for House and Senate congressional staff. The association urged the congressional offices to request the Department of Health and Human Services Office of the Inspector General to conduct a study on the quality of testing provided by Certificate of Waiver testing sites under the Clinical Laboratory Improvement Amendments and make recommendations for improvement.	Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE		130000	0	0	2020-01-13T12:45:58.380000-05:00